inhibited sexual desire

(redirected from Hypoactive sexual desire)
Also found in: Acronyms.

inhibited sexual desire

Hypoactive sexual desire, Sexual anhedonia, sexual apathy Psychology ↓ Sexual desire and interest manifest by failure to initiate or respond to a partner's initiation of sexual activity Types 1º–never had sexual desire/interest; 2º–had, no longer has, sexual interest; situational–interest in others, not current partner; general–no interest; nada. See Sexual anhedonia, Sexual aversion.
References in periodicals archive ?
Hypoactive sexual desire disorder (HSDD) is the most common sexual dysfunction in women.
A methodology study to develop and validate a screener for hypoactive sexual desire disorder in postmenopausal women, l Sex Med.
Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of route of administration and molecule type.
The role of testosterone in the treatment of hypoactive sexual desire disorder in postmenopausal women.
Sexual Outcomes in Women Treated With Sildenafil or Placebo Increased Increased Genital Sexual Sensation Satisfaction All women with female sexual Sildenafil 57% 42% arousal disorder Placebo 44% 28% Women with female sexual Sildenafil 69% 50% arousal disorder but not Placebo 41% 21% hypoactive sexual desire disorder Source: Laura Berman, Ph.
If the product is approved, it will be the first FDA-approved treatment for hypoactive sexual desire disorder.
A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of flibanserin 50 milligrams every evening and flibanserin 100 mg every evening in women with hypoactive sexual desire disorder in North America.
This case illustrates some of the challenges involved in establishing a diagnosis of female sexual dysfunction and, specifically, hypoactive sexual desire disorder (HSDD).
Recent data compared prevalence ratios for hypoactive sexual desire disorder in postmenopausal women: 2.
Young surgically menopausal women had significantly less desire, more personal stress, and higher rates of hypoactive sexual desire disorder (HSDD) than the other groups.
M2 PHARMA-June 5, 2015-Palatin Technologies gets the US FDA's recommendation for approval of flibanserin for hypoactive sexual desire disorder in women
This prompted the company to study it for hypoactive sexual desire disorder, or HSDD, an otherwise unexplained loss of sexual thoughts, fantasies and desire that can cause significant emotional distress.